Glossary

The off-ramp, defined

29 GLP-1 and weight-maintenance terms in plain English. Every definition links to the guides and tools where the concept matters.

Appetite suppression
Appetite suppression is the dampening of hunger that makes a calorie deficit feel effortless on a GLP-1. It comes from the drug's action on appetite centers in the brain and on gastric emptying. It is not permanent: when the medication clears, hunger signaling returns, often toward baseline or higher, which is the central reason regain happens. Lifestyle tools (protein, fiber, water, sleep) provide milder, durable forms of appetite control to lean on afterward.
Bioavailability
Bioavailability is the proportion of an administered dose that actually reaches systemic circulation and can have an effect. Injected GLP-1s have high bioavailability, while oral semaglutide (Rybelsus) has much lower oral absorption, which is why it must be taken on an empty stomach with specific timing and why its weight effect at approved doses is generally more modest than the higher injectable weight-management doses.
Chronic disease model of obesity
The chronic-disease model treats obesity as a long-term, relapsing medical condition with biological drivers, much like hypertension or type 2 diabetes, rather than a matter of willpower or virtue. Under this view, weight regain after stopping treatment is disease recurrence, not personal failure, and ongoing management (medication, lifestyle, or both) is expected. This framing is both more accurate to the science and central to GLP-Done's non-judgmental, identity-affirming voice.
Energy expenditure
Total energy expenditure is the sum of resting metabolic rate (the largest share), physical activity (including NEAT, the energy of everyday movement), and the thermic effect of food (energy used to digest meals). After weight loss, resting expenditure falls and stays suppressed, while appetite rises after a GLP-1, creating an energy gap. Protein (high thermic effect, muscle preservation), resistance training (muscle), and NEAT (movement) all act on energy expenditure to help close that gap.
GIP receptor
GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone involved in insulin secretion and fat metabolism. Tirzepatide activates the GIP receptor in addition to the GLP-1 receptor, and this dual action is the leading explanation for its larger average weight loss compared with GLP-1-only drugs. Research into GIP's exact role in appetite and energy balance is ongoing.
GLP-1 receptor agonist
GLP-1 receptor agonists (GLP-1 RAs) are medicines that imitate glucagon-like peptide-1, a hormone the gut releases after eating. By activating GLP-1 receptors, they signal fullness to the brain, slow how quickly the stomach empties, and help control blood sugar. That combination reduces appetite and the intrusive food thoughts many people call food noise, which is why drugs like semaglutide (Ozempic, Wegovy) and the dual agonist tirzepatide (Mounjaro, Zepbound) produce significant weight loss. When the medication stops, this signaling fades and appetite rebounds.
Habit stacking
Habit stacking is the practice of bolting a new behavior onto an established one using the form "After I [existing habit], I will [new habit]." The routine you already have becomes the cue, so starting no longer depends on remembering or feeling motivated, which is what makes the behavior automatic faster. In trials, habit-focused programs outperformed willpower-based ones, and automaticity is the mechanism: the behavior runs on a trigger rather than a daily decision. That matters most on the GLP-1 off-ramp, because routines built while appetite is still quiet keep running once food noise and hunger rebound. Stack one habit at a time and anchor it to a cue you never skip.
Lean body mass (fat-free mass)
Lean body mass, also called fat-free mass, is body weight minus fat: muscle, bone, organs, and water. Muscle is the part most relevant to weight maintenance because it drives resting metabolic rate. Rapid or unsupported weight loss takes a share of weight from muscle, which lowers metabolism and makes regain easier. Adequate protein (around 1.5 g/kg/day) and resistance training are the two evidence-based ways to protect lean mass during and after weight loss.
Leptin
Leptin is a hormone secreted by fat cells that signals energy sufficiency to the brain. As you lose fat, leptin falls in proportion, which the brain reads as a signal to eat more and conserve energy. GLP-1 medications mute hunger despite low leptin; once they stop, that protection is gone and leptin recovers only slowly, which is why regain is protracted rather than sudden. This is part of why a reduced weight is biologically defended.
Liraglutide
Liraglutide is a first-generation GLP-1 receptor agonist that requires a daily injection, unlike the newer once-weekly drugs. As Saxenda it is approved for weight management, producing average loss in the high single digits percent of body weight, less than semaglutide or tirzepatide. In the regain meta-analysis, liraglutide showed the smallest absolute rebound after stopping, largely because its on-treatment loss is smaller.
Metabolic adaptation
Metabolic adaptation (sometimes called adaptive thermogenesis) is the tendency for resting metabolic rate to fall more than body-size changes alone would predict after weight loss, so the body burns fewer calories than expected. GLP-1 medications cut appetite but do not prevent this slowdown. After stopping, the suppression persists even as appetite surges. Importantly, in isolation metabolic adaptation correlates poorly with actual regain once confounders are controlled, so it should not be overstated; hormonal and behavioral factors dominate. Preserving muscle through protein and strength training helps protect metabolic rate.
Microdosing
Microdosing refers to taking GLP-1 medications at ultra-low doses below the FDA-approved range. Obesity-medicine specialists do not recommend it, and there is no clinical evidence that sub-approved doses provide sustained benefit. For people who cannot stay on full-dose therapy, clinician-guided tapering or reduced-frequency dosing are the evidence-based alternatives. GLP-Done never promotes microdosing.
NEAT
NEAT (non-exercise activity thermogenesis) is the energy spent on everything that is not sleeping, eating, or deliberate exercise: walking, standing, fidgeting, chores, and occupational movement. It can vary by hundreds of calories a day between people, and naturally fidgety people carry an advantage in weight stability. Because it needs no willpower or gym time, NEAT shows high long-term adherence. Adding a few thousand steps a day can offset part of the appetite rebound after a GLP-1.
Protein leverage
The protein-leverage hypothesis holds that humans prioritize meeting a protein target, and will keep eating other foods until that target is reached. Diets low in protein can therefore drive overconsumption of calories. Practically, this means anchoring meals around protein helps you feel satisfied on fewer total calories. Combined with protein's high thermic effect and its role in preserving muscle, this is why protein (around 1.5 g/kg/day) is the strongest nutrition lever for keeping weight off.
Rebound weight gain
Rebound weight gain is the regain that typically follows GLP-1 discontinuation. Studies show roughly 60 to 75 percent of lost weight returns within about a year, with the steepest climb in the first 3 to 6 months. The cause is physiological: appetite hormones rebound while resting metabolic rate stays suppressed, opening an energy gap. Framing this as disease recurrence (like blood pressure rising after stopping a medication) rather than failure is both more accurate and more useful. The degree of rebound is reducible with evidence-based habits.
Resistance training
Resistance training is exercise that works muscles against a load: free weights, machines, resistance bands, or bodyweight. It is the one form of exercise shown to preserve, and even build, muscle during weight loss; in reviews, lifters gained muscle while losing weight, whereas aerobic-only and sedentary dieters lost muscle. Two to three progressive sessions a week is the evidence-based target. After a GLP-1, it protects the resting metabolic rate that buffers against the appetite rebound.
Resting metabolic rate (RMR)
Resting metabolic rate is the energy your body uses at rest to keep basic functions running, and it accounts for the majority of daily calorie burn. Muscle (fat-free mass) is the principal driver of RMR, so losing muscle lowers it and makes regain easier. After a GLP-1, protecting muscle through adequate protein and resistance training keeps RMR up exactly when appetite surges, which is why those two pillars carry the strongest evidence for maintenance.
Satiety signaling
Satiety signaling is the network of hormones and nerves that communicate fullness, including leptin from fat tissue, peptide YY (PYY) and GLP-1 from the gut, and stretch signals from the stomach. GLP-1 medications boost this signaling artificially. After stopping, satiety signals weaken (PYY drops, the GLP-1 boost is gone) while hunger signals rise, an asymmetry that defends the old, higher weight. Foods high in protein, fiber, and water support natural satiety signaling.
Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist made by Novo Nordisk. The same molecule is branded Ozempic (once-weekly injection for type 2 diabetes), Wegovy (higher-dose injection for weight management), and Rybelsus (a daily oral tablet for diabetes). In weight-management trials, semaglutide 2.4 mg produced average weight loss around 15 percent of body weight. Because it is one molecule, the off-ramp is the same across brands: stopping leads to appetite-hormone rebound and gradual regain.
SURMOUNT trial
SURMOUNT is the phase 3 trial program for tirzepatide in weight management, leading to Zepbound's approval. It showed average weight loss in the low-to-mid 20s percent of body weight at the top dose over about 72 weeks, the largest of the current GLP-1 class. As with semaglutide, withdrawal data indicate substantial regain after stopping, underscoring that maintenance planning matters regardless of how much weight was lost.
Tirzepatide
Tirzepatide is a dual agonist: it activates both the GLP-1 and GIP receptors. The added GIP activity is thought to amplify its appetite and metabolic effects, and in trials tirzepatide produced the largest average weight loss of the current class, in the low-to-mid 20s percent of body weight at the top dose. It is branded Mounjaro for type 2 diabetes and Zepbound for weight management. Larger loss on treatment can mean a larger rebound at cessation if it is not paired with a maintenance plan.
Titration
Titration is the process of starting a medication at a low dose and increasing it in stages, allowing the body to adjust and limiting side effects such as nausea. GLP-1 drugs are titrated over months from a small starting dose toward a maintenance dose. The same idea in reverse, tapering, is sometimes used when coming off. The schedule is always individualized by the prescriber based on response and tolerance.
Weight plateau
A weight plateau is a period where weight stops changing despite continued effort, as the body adapts its energy use to a new, lower weight. Plateaus are a normal part of weight regulation, both during loss and during maintenance. In maintenance, a stable plateau is the goal. Reading weight as a multi-week trend rather than a daily number helps distinguish a true plateau or drift from ordinary day-to-day noise.